| Literature DB >> 32382280 |
Si Wen1, Jiechen Zhang2, Bin Yang1, Peter M Elias3, Mao-Qiang Man1,3.
Abstract
Protective role of the skin is against external insults and maintenance of electrolyte homeostasis of the body. Cutaneous dysfunction can account for the development of both cutaneous and systemic disorders. Thus, improvements in cutaneous functions can benefit a number of extracutaneous and cutaneous functions. Resveratrol, a natural ingredient, displays multiple benefits for various systems/organs, including the skin. The benefits of resveratrol for cutaneous functions include stimulation of keratinocyte differentiation and antimicrobial peptide expression, inhibition of keratinocyte proliferation and cutaneous inflammation, UV protection, anticancer, antiaging, and inhibition of melanogenesis. The mechanisms of action of resveratrol include activation of sirtuin 1 and nuclear factor erythroid 2-related factor 2, and inhibition of mitogen-activated protein kinase signaling. Evidence suggests that topical resveratrol could be a valuable alternative not only for daily skin care, but also for the prevention and treatment of various cutaneous disorders. This review summarizes the benefits of resveratrol for cutaneous functions.Entities:
Year: 2020 PMID: 32382280 PMCID: PMC7180429 DOI: 10.1155/2020/2416837
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Structure of resveratrol.
Figure 2Synthesis of resveratrol [30].
Figure 3Biosynthesis of natural resveratrol.
Benefits of resveratrol for cutaneous functions.
| Models | Treatments | Benefits | Mechanisms | Ref. |
|---|---|---|---|---|
|
| ||||
| Keratinocytes | Cells cultured with 0.25–100 | ↓Proliferation | ND | [ |
| Cells cultured with 20 or 40 | ↓Proliferation | ↑SIRT1 | [ | |
| Cells cultured with 50 | ↓Proliferation | ND | [ | |
| Cells cultured with 25–100 | ↓Proliferation | ND | [ | |
| Cells treated with 0.197 | ↓Proliferation | ND | [ | |
| Cells cultured with 3 | ↓Differentiation | ↑SIRT1 | [ | |
| Cells cultured with 100 | ↓Proliferation | ↓Protein kinase D | [ | |
|
| ||||
|
| ||||
| Keratinocytes | Immediately after irradiation with UVA (5 J/cm2), cells were treated with 0.01–0.1 mM resveratrol for 24 hr | ↑Cell viability | ↑SOD and GSH-Px expression | [ |
| Either before or after irradiation with UVA (2.796 J/cm2), cells were treated with 2.5 and 5.0 mg/l resveratrol, respectively | ↑Cell viability | ↑NRF2 in nuclear translocation | [ | |
| Cells first treated with 10 | ↑Cell viability | ↑Activation of SIRT1 | [ | |
| Cells first treated with 2% of resveratrol for 2 hr, followed by UVB irradiation (5–100 mJ/cm2) | ↑Cell viability | ND | [ | |
| Cells treated with 5–25 | ↓NF- | ↑I | [ | |
| Cells treated with 5–10 | ↑Cell viability | ↑Nrf2 | [ | |
| Cells treated with 50 | ↓IL-6, MCP-1, and TNF- | ↑ARH | [ | |
| Cells treated with 25 or 100 | ↑ROS | ↑ERK activation | [ | |
| Cells first irradiated with 1 J/cm2 UVA +0.1 J/cm2 UVB, followed by treatment with 10 | ↓CYP1A1, CYP1B1, IL-1 | ↓Peroxide content | [ | |
| Dermal fibroblasts | Immediately after UVB irradiation (144 mJ/cm2), fibroblasts were treated with 10 or 100 | ↑Cell viability | ND | [ |
| Reconstructed human skin | Reconstructed human skin was treated with 1% of resveratrol-enriched rice extract for 24 hr, followed by irradiation with UVB (100 mJ/cm2) | ↓MMP1 | ND | [ |
| Mice | Mice were treated topically with 25 | ↓Ear weight and edema | ND | [ |
| Mice were treated topically with 10 | ↑Cell proliferation | ↓Survivin | [ | |
| Mice were treated topically with 0.48% resveratrol 20 min prior to irradiation with 360 mJ/cm2 UVB | ↓Skin edema in mice treated with resveratrol either before or after UVB irradiation | ↑NRF2 | [ | |
| Mice were treated topically with 0.48% resveratrol 20 min prior to irradiation with 180 mJ/cm2 UVB, 3 irradiation/week for a total of 30 weeks | ↓Lipid, DNA, and protein peroxidation | [ | ||
|
| ||||
|
| ||||
| Keratinocytes | Cells cultured with 20 and 60 | ↑GST activity | ↑NRF2 expression and activation | [ |
| Cells pretreated with 10 or 20 | ↑NQO1 and GSH-Px mRNA | ↑NRF2 activation | [ | |
| Cells treated with both 0.3–3 mM sodium nitroprusside and 1–30 | ↑Cell viability | ↓IL-8, NOS3, and NADPH dehydrogenase mRNA | [ | |
| Cells pretreated with 25 or 100 | ↓ROS | ND | [ | |
| Cells pretreated with 140 | ↓DNA damage and HSP70 expression | ND | [ | |
| Cells treated with 10 | ↓ROS | ND | [ | |
| Cells pretreated with 0.5–10 | ↑Scavenger receptor class B type I protein and mRNA | ND | [ | |
| Cells pretreated with 10 | ↓ROS and carbonyl groups | ↑Methionine sulfoxide reductase A mRNA | [ | |
| Cells pretreated with 0.5 | ↓Arsenic-induced increase in metabolic activity and expression of DNA polymerase beta | ND | [ | |
| Reconstructed human skin | Keratinocytes were pretreated with 20 or 100 | ↑GSH expression | ↑NRF2 activation | [ |
| Mice | Mice were treated topically with 16 | ↑GST activity and content | ↑NRF2 activation | [ |
| Mice were treated topically with 8 or 16 | ↑Glucuronosyltransferase and NADPH:quinone oxidoreductase activity | ND | [ | |
| Humans | Stratum corneum was collected with tape strip 24 hr after single application of resveratrol at a dose of 537 | ↓Production of free radical | ND | [ |
|
| ||||
|
| ||||
| Melanoma cell line | Cells were treated with 20–40 | ↓Proliferation | ↑Cells in S phase arrest | [ |
| A431 human skin carcinoma cells | A431 cells were treated with 20–100 mg/L resveratrol for 24 hr | ↑Apoptosis | ↑Activation of MAPK pathway | [ |
| A431 cells were treated with 20, 50, and 100 | ↓DNA synthesis and proliferation | ↓DNA-binding activity of AP-1 | [ | |
| Human squamous cell carcinoma cell lines | HSC2 cells were treated with both resveratrol and benzoxazinotropone at various concentrations for 48 hr | Resveratrol and benzoxazinotropone synergistically inhibited proliferation | ND | [ |
| Head and neck squamous cell carcinoma cells | Head and neck squamous cell carcinoma cells were treated with 15 and 50 | ↓Proliferation | ↑H2AX ser-139 phosphorylation | [ |
| Mice | Mice with squamous cell tumor graft were gavaged orally with 10 and 50 mg/kg body weight of resveratrol for 30 days | ↓Tumor weight and volume per mouse | ||
|
| ||||
|
| ||||
| Keratinocytes | Cells treated with 20 ng/ml TNF- | ↓IL-6 and MCP-1 | ↓Phosphorylation of I | [ |
| Cells treated with 7.5 | ↑Proliferation | ↑miR-17 expression | [ | |
| Cells treated with 50 | ↓IL-6, IL-8, MCP-1, and COX2 mRNA | ↓EGFR-ERK signaling pathway | [ | |
| Cells pretreated with 25 and 50 | ↓CCL2 and CXCL10 mRNA and protein | ↓Interferon regulatory factor 1 and phosphorylated STAT1 | [ | |
| Cells pretreated with 50 | ↓IL-6 | ND | [ | |
| Cells pretreated with 44 | ↓IL-6, IL-8, and TNF- | ND | [ | |
| Mast cells | RBL-2H3 mast cells were pretreated with 1–25 | ↓IL-3, IL-4, IL-13, and TNF- | ↓P38-MAPK, ERK1/2, JNK | [ |
| Reconstructed human skin | 3D skin was treated 10 ng/ml IFN- | ↓IL-6 | ND | [ |
| Mice | BALB/c mouse ears were treated topically with 10 mM resveratrol 2 hr prior to DNFB challenge | ↓Ear thickness | ↓Interferon regulatory factor 1 and phosphorylated STAT1 | [ |
| Following induction of allergic contact dermatitis, NC/Nga mice were treated topically with 2.5% resveratrol or resveratrol-enriched rice extract twice weekly for 5 weeks | ↓Epidermal thickness | ND | [ | |
| BALB/c mice were orally treated with resveratrol at a dose of 10 mg/kg body weight 1 hr prior to intravenous challenge with 200 | ↓IL-4 and TNF- | ↓Tyk2-STAT1 activation | [ | |
| Atopic dermatitis-like lesions were induced by topical applications of DNFB to the back of BALB/c mice for 5 weeks, followed by orally given resveratrol at a daily dose of 30 mg/kg body weight for 1 week | ↓Dermatitis scores | ND | [ | |
| Atopic dermatitis-like lesions were induced by topical applications of dermatophagoides farinae to the back of NC/Nga mice for 2 weeks, followed by orally given resveratrol at a daily dose of 20 mg/kg body weight for 2 weeks | ↓Dermatitis scores | ↓High mobility group box 1 expression | [ | |
| Psoriasis-like skin lesions were induced by topical applications of imiquimod to the back of BALB/c mice, which were orally given resveratrol at a daily dose of 400 mg/kg body weight, for 7 days. | ↓Erythema and scale scores | ND | [ | |
|
| ||||
|
| ||||
| Rats | Rats were fed with resveratrol at a daily dose of 0.5 mg/kg body weight 7 days prior to operation and continued throughout the whole experiment period | ↑Collagen deposition | ND | [ |
| Following induction of full-thickness skin wound, wound was treated topically with 225 | ↑Epithelialization | ↑AMPK pathway and SIRT1 | [ | |
| Mice | Immediately after wound, a wound dressing containing 0.04% resveratrol was applied to full-thickness skin wound for 10 days | ↓Wound size | ND | [ |
| Placing scaffolds containing 5% resveratrol on the wound for 7 days | ↓Wound size | ↑Expression of thioredoxin-1, heme oxygenase-1, and VEGF | [ | |
| Diabetic models | 0.5% resveratrol ointment was applied to wound area in diabetic rats once daily for 21 days | ↓Wound size | ↑Activity of antioxidant enzymes | [ |
| 10 | ↓Wound size | Sirt1 activation | [ | |
| Fourteen days after topical application of resveratrol (0.1 mg/ml) to wound area in diabetic rats once, wound healing was assessed | No benefit | [ | ||
Abbreviations: ND, not determined; AQP3, aquaporin 3; SOD, superoxide dismutase; MDA, malondialdehyde; GSH-Px, glutathione peroxidase; GST, glutathione S-transferase; GSH, reduced glutathione; NQO, NAD(P)H:quinone oxidoreductase; ROS: reactive oxygen species; CYP1A1, cytochrome P540 family 1 subfamily A member 1; IKKα, ΙκB kinase α; CYP1B1, cytochrome P540 family 1 subfamily B member 1; COX, cyclooxygenase; ODC, ornithine decarboxylase; NRF2, nuclear factor erythroid 2-related factor 2; ERK: extracellular signal-regulated kinase; MAPK, mitogen-activated protein kinase; JNK, c-Jun NH2-terminal kinase; TPA, 12-O-tetradecanoyl13-phorbol acetate; DNFB, 2,4-dinitro-1-fluorobenzene; NOS, nitric oxide synthase; VEGF, vascular endothelial growth factor; AMPK, adenosine monophosphate‐activated protein kinase.
Figure 4Schematic diagram of the mechanisms by which resveratrol regulates cutaneous functions. α-SMA: α-smooth muscle actin.